Press release |
Major clinical trial prompts call for change to treatment guidelines for severe malaria
The largest ever clinical trial among patients hospitalised with severe malaria has concluded that the drug artesunate should now be the preferred treatment for the disease in both children and adults worldwide. The study, funded by the Wellcome Trust, is published online in the ‘Lancet’.
An international consortium of researchers, led by Professor Nick White of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme in Bangkok, compared treatment with artesunate, which is used in Asia to treat severe malaria, to quinine, which has been in use worldwide for over three hundred years. The trial - known as the 'African quinine versus artesunate malaria trial' (AQUAMAT) - was carried out over a five-year period in hospitals across nine African countries and studied 5,425 children with severe malaria.
Severe malaria kills nearly 1 million people each year, mainly young children and pregnant women. It is caused by parasites that are injected into the bloodstream by infected mosquitoes. Severe malaria is often the main reason why children are admitted to hospital in sub-Saharan Africa, and one in ten of these children die.
For over three centuries, doctors have relied upon the bark of a South American tree to treat tropical fevers. This bark contains quinine, a bitter medicine used to flavour tonic water, which helps prevent night cramps and cure malaria. Quinine is a reliably effective drug, but it is difficult to give by injection and has unpleasant side effects, some of which are potentially dangerous.
AQUAMAT compared quinine to the more recent drug, artesunate, both given either intravenously or by intramuscular injection. The study showed that treatment with artesunate reduced the number of deaths from severe malaria by 22.5 per cent compared with quinine. With artesunate treatment 8.5 per cent of the patients died, compared to 10.9 per cent with quinine. The results were very similar in all the study sites.
Children treated with artesunate were also less likely to slip into a deeper coma or have seizures after the treatment was started. Severe hypoglycaemia - dangerously low blood sugar - was also less common in children treated with artesunate. In addition, artesunate was easy to administer, well tolerated and proved very safe.
Professor White comments: "For over a century, quinine administered by injection has been the best treatment available for treating severe malaria, but thanks to the development of the artemisinin compounds, we now have a safer and much more effective treatment. We recommend that artesunate should now replace quinine for the treatment of severe malaria in both children and adults everywhere in the world."
Artesunate is derived from a Chinese herb called qinghao (Artemisia annua). Nearly 40 years ago, Chinese scientists reported that an extract of this herb was an effective anti-malarial. These reports were treated initially with suspicion, but the compounds derived from it (such as artemisinin) have steadily gained acceptance throughout the world. In less complicated malaria cases, compounds such as artesunate are now part of the artemisinin-based combination treatments (ACTs) recommended everywhere in the world.
Five years ago the then largest ever trial in patients hospitalised with severe malaria showed that artesunate, given by injection, reduced the death rate compared with quinine. However, this trial was conducted in Asia and most of the patients studied were adults, so there was uncertainty over whether artesunate injections should replace quinine as a treatment for severe malaria in children. Today nearly all the children admitted to hospital with severe malaria in Africa still receive quinine.
Dr Arjen Dondorp, Professor White and colleagues from Mahidol University and the University of Oxford, who conducted the original study in Asia, also led the AQUAMAT study. AQUAMAT was carried out in 11 hospitals across Mozambique, Tanzania, Kenya, Uganda, Rwanda, the Democratic Republic of Congo, Nigeria, Ghana and Gambia, and involved over 200 collaborators. The trial was funded entirely by the Wellcome Trust and did not receive funding from the pharmaceutical industry.
Dr Olugbenga Mokuolu from the University of Ilorin in Nigeria, one of the trial collaborating centres, adds: "Severe malaria is a terrible burden on the African continent and across the developing world and we need the best treatments available to combat it. If half of the estimated eight million children who suffer from the disease annually could be treated with injectable artesunate, we could potentially save 100 000 young lives each year. For those of us who treat malaria in Africa, this trial is a turning point. Finally we have a better treatment to offer."
The trial has been welcomed by Sir Mark Walport, Director of the Wellcome Trust which supported both the original trial in Asia and the subsequent AQUAMAT study.
"This is an extremely important clinical trial for the treatment of malaria, showing improved survival of patients with severe malaria in Africa," says Sir Mark. "There are still many hurdles to overcome and we must be vigilant to protect against resistance to these new drugs and against a market in counterfeit drugs. Professor White and colleagues have shown that we have the potential to save the lives of hundreds of thousands of children."